Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 21, 2014; 20(15): 4189-4196
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4189
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4189
Hallmarks in colorectal cancer: Angiogenesis and cancer stem-like cells
Muriel Mathonnet, Aurelie Perraud, Niki Christou, Carole Melin, Department of Digestive Surgery, Limoges University Hospital, 87042 Limoges, France
Muriel Mathonnet, Aurelie Perraud, Hussein Akil, Carole Melin, Serge Battu, Marie-Odile Jauberteau, Homéostasie Cellulaire at Pathologies, Faculty of Medicine, University of Limoges, 87025 Limoges, France
Yves Denizot, Institut 145 GEIST, UMR CNRS 7276, Faculty of Medicine, University of Limoges, 87025 Limoges, France
Author contributions: Mathonnet M, Christou N, Akil H and Battu S analyzed the literature; Perraud A and Mathonnet M wrote the manuscript; Jauberteau MO and Denizot Y revised the manuscript; Melin C contributed to the bibliography.
Supported by Grants from the University of Limoges, Limoges University Hospital, La Ligue Contre le Cancer and the Région Limousin, which was given financial by the Comité Orientation Recherche Cancer (to Perraud A, Christou N and Akil H)
Correspondence to: Muriel Mathonnet, MD, PhD, Professor of Digestive Surgery, Department of Digestive Surgery, Limoges University Hospital, 2 Ave Martin Luther King, 87042 Limoges, France. mathonnet@unilim.fr
Telephone: +33-555-056713 Fax: +33-555-056525
Received: October 3, 2013
Revised: January 26, 2014
Accepted: March 19, 2014
Published online: April 21, 2014
Processing time: 185 Days and 16.3 Hours
Revised: January 26, 2014
Accepted: March 19, 2014
Published online: April 21, 2014
Processing time: 185 Days and 16.3 Hours
Core Tip
Core tip: Recent progress in the therapeutic treatment of colorectal cancer has resulted from targeting the hallmark stem cell-like properties of tumor cells. The survival of colorectal cancer patients has been significantly prolonged with bevacizumab, which inhibits angiogenesis providing the proliferative conditions for tumor cell growth. Personalized therapeutic approaches, centered on the angiogenic and proliferative properties of cancerous cells, could improve patient survival and decrease adverse effects induced by unnecessary chemotherapy.